Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Beyond medical expulsive therapy: evolution to supported stone passage for ureteric stones.

Portis AJ, Portis JL, Borofsky MS, Neises SM.

BJU Int. 2019 Apr;123(4):661-668. doi: 10.1111/bju.14491. Epub 2018 Sep 30.

2.

Pain is Independent of Stone Burden and Predicts Surgical Intervention in Patients with Ureteral Stones.

Portis JL, Neises SM, Portis AJ.

J Urol. 2018 Sep;200(3):597-603. doi: 10.1016/j.juro.2018.04.075. Epub 2018 Apr 30.

PMID:
29723569
3.

Unsuccessful Medical Expulsive Therapy: A Cost to Waiting?

Portis AJ, Lundquist EL, Portis JL, Glesne RE, Mercer AJ, Lundquist BA, Neises SM.

Urology. 2016 Jan;87:25-32. doi: 10.1016/j.urology.2015.07.048. Epub 2015 Sep 28.

PMID:
26416009
4.

The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3.

Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, Santiago ML, Portis JL, Hasenkrug KJ, Evans LH.

J Virol. 2010 Oct;84(20):10933-6. doi: 10.1128/JVI.01023-10. Epub 2010 Aug 11.

5.

The degree of folding instability of the envelope protein of a neurovirulent murine retrovirus correlates with the severity of the neurological disease.

Portis JL, Askovich P, Austin J, Gutierrez-Cotto Y, McAtee FJ.

J Virol. 2009 Jun;83(12):6079-86. doi: 10.1128/JVI.02647-08. Epub 2009 Apr 1.

6.

Disease-associated prion protein oligomers inhibit the 26S proteasome.

Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H, Clarke AR, van Leeuwen FW, Menéndez-Benito V, Dantuma NP, Portis JL, Collinge J, Tabrizi SJ.

Mol Cell. 2007 Apr 27;26(2):175-88.

7.

Oligodendrocytes are a major target of the toxicity of spongiogenic murine retroviruses.

Clase AC, Dimcheff DE, Favara C, Dorward D, McAtee FJ, Parrie LE, Ron D, Portis JL.

Am J Pathol. 2006 Sep;169(3):1026-38.

8.

Prion-induced amyloid heart disease with high blood infectivity in transgenic mice.

Trifilo MJ, Yajima T, Gu Y, Dalton N, Peterson KL, Race RE, Meade-White K, Portis JL, Masliah E, Knowlton KU, Chesebro B, Oldstone MB.

Science. 2006 Jul 7;313(5783):94-7.

9.
10.

Endoplasmic reticulum stress is a determinant of retrovirus-induced spongiform neurodegeneration.

Dimcheff DE, Askovic S, Baker AH, Johnson-Fowler C, Portis JL.

J Virol. 2003 Dec;77(23):12617-29.

11.

Prion proteins meet protein quality control.

Dimcheff DE, Portis JL, Caughey B.

Trends Cell Biol. 2003 Jul;13(7):337-40. Review.

PMID:
12837603
12.

Perspectives on the role of endogenous human retroviruses in autoimmune diseases.

Portis JL.

Virology. 2002 Apr 25;296(1):1-5. Review. No abstract available.

13.

N-terminal cleavage fragment of glycosylated Gag is incorporated into murine oncornavirus particles.

Fujisawa R, McAtee FJ, Favara C, Hayes SF, Portis JL.

J Virol. 2001 Nov;75(22):11239-43.

14.

Genetic determinants of neurovirulence of murine oncornaviruses.

Portis JL.

Adv Virus Res. 2001;56:3-38. Review. No abstract available.

PMID:
11450304
17.

Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae.

Igietseme JU, Portis JL, Perry LL.

Infect Immun. 2001 Mar;69(3):1832-40.

18.

Neural stem cells as tools for understanding retroviral neuropathogenesis.

Lynch WP, Portis JL.

Virology. 2000 Jun 5;271(2):227-33. Review.

19.

Brain infection by neuroinvasive but avirulent murine oncornaviruses.

Asković S, McAtee FJ, Favara C, Portis JL.

J Virol. 2000 Jan;74(1):465-73.

20.

Increased neurovirulence of polytropic mouse retroviruses delivered by inoculation of brain with infected neural stem cells.

Poulsen DJ, Favara C, Snyder EY, Portis J, Chesebro B.

Virology. 1999 Oct 10;263(1):23-9.

21.

Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae.

Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD.

J Exp Med. 1998 Sep 7;188(5):809-18.

22.
23.

Dissecting the determinants of neuropathogenesis of the murine oncornaviruses.

Portis JL, Lynch WP.

Virology. 1998 Aug 1;247(2):127-36. Review. No abstract available.

25.

Distinct homing pathways direct T lymphocytes to the genital and intestinal mucosae in Chlamydia-infected mice.

Perry LL, Feilzer K, Portis JL, Caldwell HD.

J Immunol. 1998 Mar 15;160(6):2905-14.

27.
31.
32.

Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Pincus SH, Cole R, Ireland R, McAtee F, Fujisawa R, Portis J.

J Virol. 1995 Nov;69(11):7152-8.

33.

Biological characterization and molecular cloning of murine C-type retroviruses derived from the TSZ complex from mainland China.

Bundy LM, Ru M, Zheng BF, Cheng L, Pattengale PK, Portis JL, Fan H.

Virology. 1995 Oct 1;212(2):367-82.

35.

Prevention of retrovirus-induced neurological disease by infection with a nonneuropathogenic retrovirus.

Czub M, McAtee FJ, Czub S, Lynch WP, Portis JL.

Virology. 1995 Jan 10;206(1):372-80.

37.

Kinetic analysis of spongiform neurodegenerative disease induced by a highly virulent murine retrovirus.

Czub S, Lynch WP, Czub M, Portis JL.

Lab Invest. 1994 May;70(5):711-23.

PMID:
8196367
39.
41.

Infectivity of retroviral DNA in vivo.

Portis JL, McAtee FJ, Kayman SC.

J Acquir Immune Defic Syndr (1988). 1992 Dec;5(12):1272-3. No abstract available.

PMID:
1453336
43.
45.

Complete nucleotide sequence of the neurotropic murine retrovirus CAS-BR-E.

Perryman SM, McAtee FJ, Portis JL.

Nucleic Acids Res. 1991 Apr 11;19(7):1707. No abstract available.

47.
49.
50.

Supplemental Content

Loading ...
Support Center